Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Keros Therapeutics, Inc. (KROS) had Return on Equity of -7.74% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$0.39M |
|
$-23.46M |
|
-- |
|
$0.39M |
|
$29.66M |
|
$-29.27M |
|
$4.29M |
|
$-24.98M |
|
$-24.98M |
|
$-23.46M |
|
$-23.46M |
|
$-23.46M |
|
$-23.46M |
|
$-29.27M |
|
$-28.87M |
|
37.22M |
|
37.86M |
|
$-0.38 |
|
$-0.38 |
|
| Balance Sheet Financials | |
$315.43M |
|
$4.30M |
|
$22.59M |
|
$338.02M |
|
$20.41M |
|
-- |
|
$14.47M |
|
$34.89M |
|
$303.13M |
|
$303.13M |
|
$303.13M |
|
19.54M |
|
| Cash Flow Statement Financials | |
$107.50M |
|
$-1.55M |
|
$-378.47M |
|
$561.38M |
|
$288.86M |
|
$-272.52M |
|
$28.70M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.45 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-7602.40% |
|
-7602.41% |
|
-- |
|
-6486.85% |
|
-6093.61% |
|
$105.95M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.07 |
|
1359.78 |
|
|
Return on Equity |
-7.74% |
-7.74% |
|
-6.94% |
|
-7.74% |
|
$15.51 |
|
$2.80 |
|
$2.84 |
|